Table 5.
Summary of included studies’ adverse events
| Trials | Iris or retinal neovascularization | Anterior chamber reaction | Endophthalmitis | Lens opacity progression | Ocular hypertension | Fluorescein angiography reduced leakage and edema | Blindness | Fibrous proliferation | Death |
|---|---|---|---|---|---|---|---|---|---|
| Ahmadieh et al20 | Zero | IVB 19.5% IVB/IVT 18.9% |
No data | Zero | 3 eyes IVB/IVT groups | No data | 1 eye in IVB group (2.4%) | 1 patient in control group | |
| Cunningham et al21 | Zero | 1 injection out of 652 in IVP dose | Zero | No data | |||||
| Scott et al22 | 1 post injection | No data | 1 eyes IVB 1.25 mg | Zero | 1 patient pancreatic cancer | ||||
| Soheilian et al23 | 3 eyes IVB 2 eyes IVB/IVT 2 eyes laser |
7 eyes (18.9%) in IVB 4 eyes (12.1%) in IVB/IVT | No data | Zero | 3 eyes in IVB/IVT group | IVB 26 (70.2%) IVB/IVT 19 (57.6%) Laser 17 (51.5%) |
No data | ||
| Paccola et al24 | Zero | Zero | Zero | Zero | 3 eyes in IVB/IVT group significant increase in IVT group compared to IVB | Zero |
Abbreviations: IVB, intravitreal bevacizumab; IVP, intravitreal pegaptanib; IVT, intravitreal triamcinolone.